Chronic arthritis aggravates vascular lesions in rabbits with atherosclerosis: A novel model of atherosclerosis associated with chronic inflammation

Arthritis and Rheumatism

Volumn 58, Issue 9, 2008, Pages 2723-2734

  Largo, Raquel ^a,b   Sánchez Pernaute, Olga ^a   Marcos, M Esther ^a   Moreno Rubio, Juan ^a   Aparicio, César ^b   Granado, Rosario ^c   Ortega, Luis ^d   Egido, Jesús ^a   Herrero Beaumont, Gabriel ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^c HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

^d HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; C REACTIVE PROTEIN; CYCLOOXYGENASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; OVALBUMIN; PROSTAGLANDIN E2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; CHRONIC ARTHRITIS; CHRONIC INFLAMMATION; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE ACTIVITY; DISEASE EXACERBATION; DISEASE SEVERITY; ENDOTHELIUM INJURY; ENDOTHELIUM LESION; FEMORAL ARTERY; MACROPHAGE MIGRATION; MALE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; RABBIT; SYNOVITIS; SYNOVIUM; VASCULAR LESION;

ANIMALS; ARTHRITIS, EXPERIMENTAL; ATHEROSCLEROSIS; C-REACTIVE PROTEIN; CHEMOKINE CCL2; CYCLOOXYGENASE 2; DINOPROSTONE; ELECTROPHORETIC MOBILITY SHIFT ASSAY; INFLAMMATION; INTERLEUKIN-6; LEUKOCYTES, MONONUCLEAR; LIPIDS; MALE; NF-KAPPA B; RABBITS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STATISTICS, NONPARAMETRIC; SYNOVIAL MEMBRANE; TUNICA INTIMA; TUNICA MEDIA;

EID: 51849095954     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.23765     Document Type: Article

References (63)

1. Van Leuven SI, Franssen R, Kastelein JJ, Levi M, Stroes ES, Tak PP. Systemic inflammation as a risk factor for atherothrombosis. Rheumatology (Oxford) 2008;47:3-7.
2. Abou-Raya A, Abou-Raya S. Inflammation: a pivotal link between autoimmune diseases and atherosclerosis. Autoimmun Rev 2006;5:331-7.
3. Park YB, Lee SK, Lee WK, Suh CH, Lee CW, Lee CH, et al. Lipid profiles in untreated patients with rheumatoid arthritis. J Rheumatol 1999;26:1701-4.
4. Park YB, Ahn CW, Choi HK, Lee SH, In BH, Lee HC, et al. Atherosclerosis in rheumatoid arthritis: morphologic evidence obtained by carotid ultrasound. Arthritis Rheum 2002;46:1714-9.
5. Dessein PH, Joffe BI, Singh S. Biomarkers of endothelial dysfunction, cardiovascular risk factors and atherosclerosis in rheumatoid arthritis. Arthritis Res Ther 2005;7:R634-43.
6. Van Doornum S, McColl G, Wicks IP. Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis? [review]. Arthritis Rheum 2002;46:862-73.
7. Banks M, Flint J, Bacon PA, Kitas GD. Rheumatoid arthritis is an independent risk factor for ischaemic heart disease [abstract]. Arthritis Rheum 2000;43 Suppl 9:S385.
8. Gabriel SE, Crowson CS, Maradit Kremers H, Doran MF, Turesson C, O'Fallon WM, et al. Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years. Arthritis Rheum 2003;48:54-8.
9. Del Rincon ID, Williams K, Stern MP, Freeman GL, Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001;44:2737-45.
10. Westerweel PE, Luyten RK, Koomans HA, Derksen RH, Verhaar MC. Premature atherosclerotic cardiovascular disease in systemic lupus erythematosus [review]. Arthritis Rheum 2007;56:1384-96.
11. Hall FC, Dalbeth N. Disease modification and cardiovascular risk reduction: two sides of the same coin? Rheumatology (Oxford) 2005;44:1473-82.
12. Sattar N, McCarey DW, Capell H, McInnes IB. Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003;16:2957-63.
13. Roman MJ, Devereux RB, Schwartz JE, Lockshin MD, Paget SA, Davis A, et al. Arterial stiffness in chronic inflammatory diseases. Hypertension 2005;46:194-9.
14. Stanic AK, Stein CM, Morgan AC, Fazio S, Linton MF, Wakeland EK, et al. Immune dysregulation accelerates atherosclerosis and modulates plaque composition in systemic lupus erythematosus. Proc Natl Acad Sci U S A 2006;103:7018-23.
15. Bacon PA, Townend JN. Nails in the coffin: increasing evidence for the role of rheumatic disease in the cardiovascular mortality of rheumatoid arthritis [editorial]. Arthritis Rheum 2001;44:2707-10.
16. Gualillo O, Gonzalez-Juanatey JR, Lago F. The emerging role of adipokines as mediators of cardiovascular function: physiologic and clinical perspectives. Trends Cardiovasc Med 2007;17:275-83.
17. Lago F, Dieguez C, Gomez-Reino J, Gualillo O. The emerging role of adipokines as mediators of inflammation and immune responses. Cytokine Growth Factor Rev 2007;18:313-25.
18. Toh ML, Miossec P. The role of T cells in rheumatoid arthritis: new subsets and new targets. Curr Opin Rheumatol 2007;19:284-8.
19. Feldmann M, Brennan FM, Maini RN. Rheumatoid arthritis. Cell 1996;3:307-10.
20. Palacios I, Lopez-Armada MJ, Hernandez P, Sanchez-Pernaute O, Gutierrez S, Miguelez R, et al. Tenidap decreases IL-8 and monocyte chemotactic peptide-1 (MCP-1) mRNA expression in the synovial tissue of rabbits with antigen arthritis and in cultured synovial cells. Clin Exp Immunol 1998;111:588-96.
21. Manzi S, Wasko MC. Inflammation-mediated rheumatic diseases and atherosclerosis. Ann Rheum Dis 2000;59:321-5.
22. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005;352:1685-95.
23. Schonbeck U, Sukhova GK, Graber P, Coulter S, Libby P. Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am J Pathol 1999;155:1281-91.
24. 2-dependent plaque instability. Circulation 2001;104:921-7.
25. Gomez-Hernandez A, Martin-Ventura JL, Sanchez-Galan E, Vidal C, Ortego M, Blanco-Colio LM, et al. Overexpression of COX-2, prostaglandin E synthase-1 and prostaglandin E receptors in blood mononuclear cells and plaque of patients with carotid atherosclerosis: regulation by nuclear factor-κB. Atherosclerosis 2006;187:139-49.
26. LeVeen RF, Wolf GL, Villanueva TG. New rabbit atherosclerosis model for the investigation of transluminal angioplasty. Invest Radiol 1982;17:470-5.
27. Hernandez-Presa M, Bustos C, Ortego M, Tunon J, Renedo G, Ruiz-Ortega M, et al. Angiotensin-Converting enzyme inhibition prevents arterial nuclear factor-κB activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. Circulation 1997;95:1532-41.
28. Hernandez-Presa MA, Martin-Ventura JL, Ortego M, Gomez-Hernandez A, Tunon J, Hernandez-Vargas P, et al. Atorvastatin reduces the expression of cyclooxygenase-2 in a rabbit model of atherosclerosis and in cultured vascular smooth muscle cells. Atherosclerosis 2002;160:49-58.
29. Vidal C, Gomez-Hernandez A, Sanchez-Galan E, Gonzalez A, Ortega L, Gomez-Gerique JA, et al. Licofelone, a balanced inhibitor of cyclooxygenase and 5-lipoxygenase, reduces inflammation in a rabbit model of atherosclerosis. J Pharmacol Exp Ther 2007;320:108-16.
30. Howson P, Shepard N, Mitchell N. The antigen induced arthritis model: the relevance of the method of induction to its use as a model of human disease. J Rheumatol 1986;13:379-90.
31. Benito MJ, Sanchez-Pernaute O, Lopez-Armada MJ, Hernandez P, Palacios I, Egido J, et al. Cyclosporin A prevents the histologic damage of antigen arthritis without inducing fibrosis. Arthritis Rheum 2000;43:311-9.
32. Sanchez-Pernaute O, Lopez-Armada MJ, Calvo E, Diez-Ortego I, Largo R, Egido J, et al. Fibrin generated in the synovial fluid activates intimai cells from their apical surface: a sequential morphological study in antigen-induced arthritis. Rheumatology (Oxford) 2003;42:19-25.
33. Krenn V, Morawietz L, Haupl T, Neidel J, Petersen I, Konig A. Grading of chronic synovitis - a histopathological grading system for molecular and diagnostic pathology. Pathol Res Pract 2002;198:317-25.
34. Alvarez-Soria MA, Largo R, Santillana J, Sanchez-Pernaute O, Calvo E, Hernandez M, et al. Long term NSAID treatment inhibits COX-2 synthesis in the knee synovial membrane of patients with osteoarthritis: differential proinflammatory cytokine profile between celecoxib and aceclofenac. Ann Rheum Dis 2006;65:998-1005.
35. Largo R, Alvarez-Soria MA, Diez-Ortego I, Calvo E, Sanchez-Pernaute O, Egido J, et al. Glucosamine inhibits IL-1β-induced NFκB activation in human osteoarthritic chondrocytes. Osteoarthritis Cartilage 2003;11:290-8.
36. Firestein GS. Rheumatoid arthritis: etiology and pathogenesis of rheumatoid arthritis. In: Harris ED Jr, Budd RC, Firestein GS, Genovese MC, Sergent JS, Ruddy S, Sledge CB, editors. Kelley's textbook of rheumatology. 7th ed. Philadelphia: Elsevier Saunders; 2005. p. 996-1042.
37. Danenberg HD, Welt FG, Walker M III, Seifert P, Toegel GS, Edelman ER. Systemic inflammation induced by lipopolysaccharide increases neointimal formation after balloon and stent injury in rabbits. Circulation 2002;105:2917-22.
38. Takaoka M, Uemura S, Kawata H, Imagawa K, Takeda Y, Nakatani K, et al. Inflammatory response to acute myocardial infarction augments neointimal hyperplasia after vascular injury in a remote artery. Arterioscler Thromb Vasc Biol 2006;26:2083-9.
39. Murrell M, Khachigian L, Ward MR. The role of c-jun in PDTC-sensitive flow-dependent restenosis after angioplasty and stenting. Atherosclerosis 2007;194:364-71.
40. Miller AM, McPhaden AR, Preston A, Wadsworth RM, Wainwright CL. TNFα increases the inflammatory response to vascular balloon injury without accelerating neointimal formation. Atherosclerosis 2005;179:51-9.
41. Zhou Z, Lauer MA, Wang K, Forudi F, Zhou X, Song X, et al. Effect of anti-tumor necrosis factor-α polyclonal antibody on restenosis after balloon angioplasty in a rabbit atherosclerotic model. Atherosclerosis 2002;161:153-9.
42. Burleigh ME, Babaev VR, Oates JA, Harris RC, Gautam S, Riendeau D, et al. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice. Circulation 2002;105:1816-23.
43. Peters W, Charo IF. Involvement of chemokine receptor 2 and its ligand, monocyte chemoattractant protein-1, in the development of atherosclerosis: lessons from knockout mice. Curr Opin Lipidol 2001;12:175-80.
44. Koenig W, Khuseyinova N. Biomarkers of atherosclerotic plaque instability and rupture. Arterioscler Thromb Vasc Biol 2007;27:15-26.
45. Shankavaram UT, Lai WC, Netzel-Arnett S, Mangan PR, Ardans JA, Caterina N, et al. Monocyte membrane type 1-matrix metalloproteinase: prostaglandin-dependent regulation and role in metalloproteinase-2 activation. J Biol Chem 2001;276:19027-32.
46. Wesley RB II, Meng X, Godin D, Galis ZS. Extracellular matrix modulates macrophage functions characteristic to atheroma: collagen type I enhances acquisition of resident macrophage traits by human peripheral blood monocytes in vitro. Arterioscler Thromb Vasc Biol 1998;18:432-40.
47. Nomoto K, Oguchi S, Watanabe I, Kushiro T, Kanmatsuse K. Involvement of inflammation in acute coronary syndromes assessed by levels of high-sensitivity C-reactive protein, matrix metalloproteinase-9 and soluble vascular-cell adhesion molecule-1. J Cardiol 2003;42:201-6.
48. Watanabe S, Mu W, Kahn A, Jing N, Li JH, Lan HY, et al. Role of JAK/STAT pathway in IL-6-induced activation of vascular smooth muscle cells. Am J Nephrol 2004;24:387-92.
49. Choi EK, Park HJ, Ma JS, Lee HC, Kang HC, Kim BG, et al. LY294002 inhibits monocyte chemoattractant protein-1 expression through a phosphatidylinositol 3-kinase-independent mechanism. FEBS Lett 2004;559:141-4.
50. Hattori Y, Matsumura M, Kasai K. Vascular smooth muscle cell activation by C-reactive protein. Cardiovasc Res 2003;58:186-95.
51. Chang LT, Sun CK, Chiang CH, Wu CJ, Chua S, Yip HK. Impact of simvastatin and losartan on antiinflammatory effect: in vitro study. J Cardiovasc Pharmacol 2007;49:20-6.
52. -/- mice. Arterioscler Thromb Vasc Biol 2006;26:143-9.
53. Klimiuk PA, Sierakowski S, Latosiewicz R, Cylwik JP, Cylwik B, Skowronski J, et al. Circulating tumour necrosis factor α and soluble tumour necrosis factor receptors in patients with different patterns of rheumatoid synovitis. Ann Rheum Dis 2003;62:472-5.
54. Klimiuk PA, Sierakowski S, Latosiewicz R, Cylwik JP, Cylwik B, Skowronski J, et al. Interleukin-6, soluble interleukin-2 receptor and soluble interleukin-6 receptor in the sera of patients with different histological patterns of rheumatoid synovitis. Clin Exp Rheumatol 2003;21:63-9.
55. Klimiuk PA, Sierakowski S, Latosiewicz R, Skowronski J, Cylwik JP, Cylwik B, et al. Histological patterns of synovitis and serum chemokines in patients with rheumatoid arthritis. J Rheumatol 2005;32:1666-72.
56. Yao TC, Kuo ML, See LC, Ou LS, Lee WI, Chan CK, et al. RANTES and monocyte chemoattractant protein 1 as sensitive markers of disease activity in patients with juvenile rheumatoid arthritis: a six-year longitudinal study. Arthritis Rheum 2006;54:2585-93.
57. Kalantar-Zadeh K, Block G, Horwich T, Fonarow GC. Reverse epidemiology of conventional cardiovascular risk factors in patients with chronic heart failure. J Am Coll Cardiol 2004;43:1439-44.
58. Liu Y, Coresh J, Eustace JA, Longenecker JC, Jaar B, Fink NE, et al. Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA 2004;291:451-9.
59. Greenberg AS, Nordan RP, McIntosh J, Calvo JC, Scow RO, Jablons D. Interleukin 6 reduces lipoprotein lipase activity in adipose tissue of mice in vivo and in 3T3-L1 adipocytes: a possible role for interleukin 6 in cancer cachexia. Cancer Res 1992;52:4113-6.
60. Attman PO, Alaupovic P, Tavella M, Knight-Gibson C. Abnormal lipid and apolipoprotein composition of major lipoprotein density classes in patients with chronic renal failure. Nephrol Dial Transplant 1996;11:63-9.
61. Roubenoff R, Roubenoff RA, Cannon JG, Kehayias JJ, Zhuang H, Dawson-Hughes B, et al. Rheumatoid cachexia: cytokine-driven hypermetabolism accompanying reduced body cell mass in chronic inflammation. J Clin Invest 1994;93:2379-86.
62. Svenson KL, Lundqvist G, Wide L, Hallgren R. Impaired glucose handling in active rheumatoid arthritis: effects of corticosteroids and antirheumatic treatment. Metabolism 1987;36:944-8.
63. Roubenoff R, Roubenoff RA, Ward LM, Holland SM, Hellmann DB. Rheumatoid cachexia: depletion of lean body mass in rheumatoid arthritis: possible association with tumor necrosis factor. J Rheumatol 1992;19:1505-10.